Efficacy of tocilizumab treatment in severely ill COVID-19 patients

Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.

Authors

Jie Zhao¹, Wei Cui¹, Bao-Ping Tian²

Affiliations

¹ Department of Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd., Hangzhou, 310009, Zhejiang, China.
² Department of Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd., Hangzhou, 310009, Zhejiang, China. TianBP@zju.edu.cn.

No abstract available

Keywords: COVID-19; Efficacy; Meta-analysis; Tocilizumab.

Publication types

Letter
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy
Humans
Randomized Controlled Trials as Topic
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab